Introduction {#Sec1}
============

Diterpenoid alkaloids are the main pharmacological constituents of *Aconitum*. Diterpenoid alkaloids have anti-inflammatory, analgesic, sedative, antipyretic, and antineoplastic effection; the weight of them is accounting for about 7%--10% of *Aconitum*. Yunaconitine **(1)**, as a C-19 diester diterpene alkaloid, distributes in almost the whole Yunnan Province; *Aconitum hemsleyanum* and *A. geniculatum* contains yunaconitine **(1)** \[[@CR1]--[@CR3]\] abundantly. However, **1** has very strong toxicity (LD~50~ for mice is 585 μg/kg (i.p.), for rats is 50 μg/kg (i.v.), and for dogs is 30 μg/kg (i.v.) \[[@CR4]\].). Additionally, although crassicauline A **(3)** has high treatment index, low toxicity, strong analgesic activity and no pain tolerance, it is lack of contents in *Aconitum* \[[@CR5]--[@CR9]\]. Moreover **3** \[[@CR10]\] exists in a tiny minority of *Acontium s*pecies that produced in Li Jiang, Yunnan, China. Hence, there is a high cost in the application of **3**. At present, **3** has been widely used in clinical treatment for more than 30 years in China \[[@CR4]\] including the treatment of rheumatoid arthritis, osteoarthritis, neuropathic and chronic pain. The main available dosage forms of crassicauline A **(3)** on the market include tablets, capsules, injections. Some studies have shown the subtle difference between **1** and **3**: Yunaconitine **(1)** contains a α-hydroxyl group at C-3; we believe that partial synthesis of **3** from **1** deserves to be mentioned.

A patent published by Zhang et al. \[[@CR3]\] has reported four partial synthesis methods to afford crassicauline A **(3)** but the methods are complicated and difficult to purify the products with low yield. Therefore, we try to obtain semi synthetic **3** on the basis of increasing yield and getting a concise route.

Results, Discussion and Conclusion {#Sec2}
==================================

At first, yunaconitine **(1)** was treated with thionyl chloride to acquire a dehydration product. Then the product was treated with silica gel column chromatography. After that, dehydroyunaconitine **(2)** (Fig. [1](#Fig1){ref-type="fig"}) was obtained. The ^1^H NMR spectra (*δ*~H~ 6.01, 5.77) and ^13^C NMR spectra (*δ*~C~ 137.6, 125.3) of **2** illustrated the presence of a double bond at C-2. Besides, in HRESIMS^+^, a quasi-molecular ion peak appeared at *m/z* 642 \[M+H\]^+^; we could totally confirmed the double bond again. Lastly, under hydrogen reduction with Raney Ni catalysis, dehydroyunaconitine **(2)** converted to another product **3** (Fig. [1](#Fig1){ref-type="fig"}) which showed the same data (^1^H NMR, ^13^C NMR, ESIMS) as standard sample of crassicauline A. In this way, semi synthesis of crassicauline A **(3)** from yunaconitine **(1)** had been completed.Fig. 1Chemical transformation of **1** to **3**

We reported a new method to acquire crassicauline A **(3)**, which had not been reported in the literature before. In our research, the semi synthesis of **3** from dehydroyunaconitine **(2)** was one of the most difficult steps. After a series of unsuccessful experiments, we finally found a practicable method. Compared with other methods, this one below was more suitable for production application and more concise; moreover, the cost was lower with higher yield.

In summary, we would continue to study the nature of yunaconitine **(1)** further. Previous studies have shown that (C-3, C-8, C-14) bonds of yunaconitine **(1)** have high pharmacological activity. Hence, we would tentatively synthesize a series of derivatives and establish some drug models in mice firstly; then, we expect to find better analgesic effect and fewer side effects with lower toxic compounds. Generally, this subject would be very useful for studies of structure--function relationship regard to diterpenoid alkaloids.

Experimental Sections {#Sec3}
=====================

UV spectra were measured on a UV 210A Shimadzu spectrometer. IR spectra were recorded on a Vector 22 spectrometer with KBr pellets. Optical rotations were measured on Rudolph Autopol VI polarimeter. (Rudolph Research Analytical, Hacketstown, NJ, USA).One-dimensional NMR spectra were recorded with Avance spectrometer operating at 400 MHz for ^1^H and at 100 MHz for ^13^C. The chemical shifts (*δ*) were measured in CDCl~3~ (solvent signals: *δ*~H~ 7.24, *δ*~C~ 76.90) with TMS as an internal standard. ESI mass spectra were recorded on VG Auto Spec-3000 spectrometer.

Separation of Yunaconitine (**1**) {#Sec4}
----------------------------------

In a normal method \[[@CR11]\], firstly, we crushed the roots of *A. hemsleyanum* or *A. geniculatum* into powders. Secondly, above-mentioned powders (1.5 kg) were soaked by 10% sodium carbonate and extracted with chloroform. Thirdly, the concentrated extracts were diluted with water and acidified with 2% hydrochloric acid. Fourthly, the liquor from last step was filtered; the filter liquor was alkalized with ammonium hydroxide and extracted with ether. Lastly, the ether solvent was dried over anhydrous sodium sulfate and concentrated under vacuum to acquire yunaconitine **(1)** (15.6 g, yield: 1.04%). After the final step, **1** was recrystallized several times by using ether to form crystals.

Preparation of Dehydroyunaconitine (**2**) {#Sec5}
------------------------------------------

At first, yunaconitine **(1)** (1.07 g) was dissolved in thionyl chloride (15 ml) and the resulting mixture in a round bottom flask was refluxed at 80 ℃ for 11 h. In the second step, the mixture above was filtered and the filter liquor was evaporated to dryness under reduced pressure to give a residue (1.45 g). Thirdly, the residue was dissolved in H~2~O and alkalized to pH 8 with saturated sodium carbonate. After that, the liquor from last step was extracted with dichloromethane and the dichloromethane solvent was dried over anhydrous sodium sulfate. Finally, the above-mentioned solvent was concentrated under vacuum to obtain dehydroyunaconitine **(2)** and the compound was purified with silica gel column chromatography (eluted with acetone: petroleum ether 3:7; chloroform: methanol 9.5:0.5, respectively) to afford the pure product **2**. (836 mg, yield: 80.3%). **2** could be recrystallized by using acetone: n-hexane mixed in specific proportion to form crystals.
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Preparation of Crassicauline A (**3**) {#Sec6}
--------------------------------------

Firstly, dehydroyunaconitine **(2)** (250 mg) was dissolved in 95% ethanol (5 mL) and under hydrogen reduction with Raney Ni catalysis (1.5 g), the resulting mixture in a round bottom flask was stirred at room temperature for 8 h. Next, after reaction was completed, the Raney Ni was removed by filtration. Lastly, the filter liquor was evaporated to dryness under reduced pressure to acquire a product **3** as white powders (238 mg, yield: 94.9%).

**3** had the same data (^1^H NMR, ^13^C NMR, ESIMS) as standard sample of crassicauline A; the ^13^C NMR spectra of **3** see Table [1](#Tab1){ref-type="table"}. At the same time, **3** also showed the same spot as crassicauline A in thin-layer chromatography. Therefore, the product **3** could be proved to be crassicauline A.
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